Mechanisms of resistance to trastuzumab as neoadjuvant therapy in women with HER2-overexpressing operable breast cancer.

被引：0
|
作者：
Jinno, Hiromitsu
Sato, Tomomi
Hayashida, Tetsu
Takahashi, Maiko
Hirose, Shigemichi
Kitagawa, Yuko
机构：
[1] Keio Univ, Sch Med, Tokyo, Japan
[2] Keio Univ, Sch Med, Dept Surg, Tokyo 160, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11060
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Downregulation of Erbin in Her2-overexpressing breast cancer cells promotes cell migration and induces trastuzumab resistance
    Liu, Dan
    Shi, Ming
    Duan, Chenyang
    Chen, Hongyu
    Hu, Yabin
    Yang, Zhengyan
    Duan, Huijun
    Guo, Ning
    MOLECULAR IMMUNOLOGY, 2013, 56 (1-2) : 104 - 112
  • [32] Trastuzumab-targeted gene delivery to Her2-overexpressing breast cancer cells
    Mann, K.
    Kullberg, M.
    CANCER GENE THERAPY, 2016, 23 (07) : 221 - 228
  • [33] Neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for HER-2-positive operable breast cancer - Reply
    Buzdar, AU
    Theriault, RL
    Hunt, KK
    Hortobagyi, GN
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (30) : 7760 - 7761
  • [34] A phase II neoadjuvant trial of concurrent trastuzumab and paclitaxel without anthracycline in women with HER2-positive operable breast cancer.
    Jinno, H.
    Hayashida, T.
    Takahashi, M.
    Hirose, S.
    Kitagawa, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (27)
  • [35] Overcoming trastuzumab resistance in HER2-overexpressing breast cancer by utilizing PHB2, a tumor suppressor of multiple resistance pathways
    Yoshimaru, Tetsuro
    Matsushita, Yosuke
    Sasa, Mitsunori
    Miyoshi, Yasuo
    Katagiri, Toyomasa
    CANCER RESEARCH, 2018, 78 (13)
  • [36] Relationship between weight change and response to trastuzumab-based neoadjuvant chemotherapy among women with operable HER2 overexpressing breast cancer
    Hajjaji, Nawale
    Chocteau, Dorothee
    Gerard, Sylvie
    Orgerie, Brigitte
    CANCER RESEARCH, 2014, 74 (19)
  • [37] Phase I/II trail of everoiimus (RAD001) and trastuzumab in patients with trastuzumab-resistant, HER2-overexpressing breast cancer.
    Morrow, P. H.
    Wulf, G. M.
    Booser, D. J.
    Moore, J. A.
    Flores, P. R.
    Krop, I. E.
    Winer, E. P.
    Hortobagyi, G. N.
    Yu, D.
    Esteva, F. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [38] Predictors of Locoregional Outcome in HER2-Overexpressing Breast Cancer Treated With Neoadjuvant Chemotherapy
    Arsenault, Daniel
    Hurley, Judith
    Takita, Cristiane
    Reis, Isildinha M.
    Zhao, Wei
    Rodgers, Steven
    Wright, Jean L.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2015, 38 (04): : 348 - 352
  • [39] Taxanes Plus Trastuzumab Compared To Oral Vinorelbine Plus Trastuzumab in HER2-Overexpressing Metastatic Breast Cancer
    Bergen, Elisabeth
    Berghoff, Anna S.
    Rudas, Margaretha
    Dubsky, Peter
    De Vries, Catharina
    Sattlberger, Claudia
    Mader, Robert M.
    Zagouri, Flora
    Sparber, Cornelia
    Fitzal, Florian
    Gnant, Michael
    Rottenfusser, Andrea
    Zielinski, Christoph C.
    Preusser, Matthias
    Steger, Guenther G.
    Bartsch, Rupert
    BREAST CARE, 2014, 9 (05) : 344 - 348
  • [40] Pulsed-laser irradiation of multifunctional gold nanoshells to overcome trastuzumab resistance in HER2-overexpressing breast cancer
    Toni Nunes
    Thomas Pons
    Xue Hou
    Khanh Van Do
    Benoît Caron
    Marthe Rigal
    Mélanie Di Benedetto
    Bruno Palpant
    Christophe Leboeuf
    Anne Janin
    Guilhem Bousquet
    Journal of Experimental & Clinical Cancer Research, 38
12345